Cargando…

Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022

Studying the prevalence of SARS-CoV-2 specific antibodies (seroprevalence) allows for assessing the impact of epidemic containment measures and vaccinations and estimating the number of infections regardless of viral testing. We assessed antibody-mediated immunity to SARS-CoV-2 induced by infections...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solastie, Anna, Nieminen, Tuomo, Ekström, Nina, Nohynek, Hanna, Lehtonen, Lasse, Palmu, Arto A., Melin, Merit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291939/ https://www.ncbi.nlm.nih.gov/pubmed/37289188 http://dx.doi.org/10.1080/22221751.2023.2222849

Ejemplares similares

Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
por: Haveri, Anu, et al.
Publicado: (2022)

Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
por: Haveri, Anu, et al.
Publicado: (2021)

Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection
por: Ekström, Nina, et al.
Publicado: (2022)

High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
por: Dub, Timothée, et al.
Publicado: (2022)

Underreporting of SARS-CoV-2 infections during the first wave of the 2020 COVID-19 epidemic in Finland—Bayesian inference based on a series of serological surveys
por: Nieminen, Tuomo A., et al.
Publicado: (2023)

Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021
por: Poukka, Eero, et al.
Publicado: (2022)

High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
por: Baum, Ulrike, et al.
Publicado: (2022)

Understanding the impact of rapid antigen tests on SARS-CoV-2 transmission in the fifth wave of COVID-19 in Hong Kong in early 2022
por: Du, Zhanwei, et al.
Publicado: (2022)

Assessing SARS-CoV-2 vaccine hesitancy among the people living with and without HIV from May to September 2022 in Blantyre, Malawi
por: Mchawa, Chifundo, et al.
Publicado: (2023)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China
por: Yin, Zhiying, et al.
Publicado: (2023)

Incidence of sinus thrombosis with thrombocytopenia—A nation-wide register study
por: Hovi, Petteri, et al.
Publicado: (2023)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Susceptibility of rabbits to SARS-CoV-2
por: Mykytyn, Anna Z., et al.
Publicado: (2021)

Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022
por: Cheung, Pak-Hin Hinson, et al.
Publicado: (2022)

Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China
por: Zheng, Liwei, et al.
Publicado: (2023)

SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients: SARS-CoV-2 infection impairs islet function
por: Ji, Ningfei, et al.
Publicado: (2022)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
por: Liang, Huang, et al.
Publicado: (2022)

SARS-CoV-2 reinfection and COVID-19 severity
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
por: Huang, Qingrui, et al.
Publicado: (2022)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice
por: Huang, Qing, et al.
Publicado: (2023)

The ecology of viruses in urban rodents with a focus on SARS-CoV-2
por: Fisher, Adam M., et al.
Publicado: (2023)

A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies
por: Solastie, Anna, et al.
Publicado: (2021)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

A second functional furin site in the SARS-CoV-2 spike protein
por: Zhang, Yue, et al.
Publicado: (2022)

The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
por: Yu, Haiyun, et al.
Publicado: (2023)

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants
por: Fan, Feng, et al.
Publicado: (2023)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
por: Criscuolo, Elena, et al.
Publicado: (2021)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters
por: Field, C. J., et al.
Publicado: (2022)

SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay
por: Elizondo, Victoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ssro1ltlsp02k1dcieosvgg8hd